Inclusion Criteria:

- Histopathology of primary tumors: all but primary small cell cancer, germ cell
tumors, leukemia, lymphoma, or primary central nervous system.

- Primary-site: controlled, meaning operated and / or irradiated; without detectable
local tumor activity

- Lack of extra-cranial metastases

- Absence of prior brain irradiation

- Number of brain metastases: 1-3

- Location of brain metastases: brain regions eligible for surgery (non-eloquent areas)
and RC (metastases with largest diameter ≤ 3 cm, volume <15 mL, and> 5 mm from the
optic chiasm, optic nerves, thalamus, hypothalamus, basal ganglia base, optic tract,
optic radiation, midbrain, pons, medulla, corpus callosum, internal capsule,
hippocampus and amygdala, and <10 ml of brain tissue receiving ≥ 12 Gy).

- Metastasis-that does not cause significant mass effect and hydrocephalus or
herniation requiring urgent surgical intervention

- Second uncontrolled primary tumor site: none, except non-melanoma skin cancer

- Absence of comorbid conditions that prevents surgery for resection of brain
metastases

- Absence of connective tissue disease such as lupus erythematosus or scleroderma

- Patients in chemotherapy need to have their chemotherapy treatment suspended.

- Patients must consent to be followed by clinical staff of the Barretos Cancer
Hospital (HCB).

- KPS: ≥ 70%

- Neutrophils ≥ 1800 cells / mL until 14 days prior to study entry

- Platelets ≥ 100,000 cells / mL until 14 days prior to study entry

- Hemoglobin ≥ 10 g / dL 14 days prior to entering the study (transfusion is allowed to
achieve required concentration)

- Creatinine ≤ 1.7 mg / dL 14 days prior to study entry

- BUN ≤ 30 mg / dL 14 days prior to entry on study

- Bilirubin ≤ 2 mg / dL 14 days prior to study entry

- TGO/TGP Up to three times normal on examination until 14 days prior to study entry
Prothrombin time-INR <1.4 at examination until 14 days prior to study entry

- Systolic pressure ≤ 160 mm Hg and diastolic pressure ≤ 90 mm Hg at examination until
14 days prior to study entry Electrocardiogram-without acute myocardial infarction in
examination until 14 days prior to study entry

- No active bleeding or pathological condition that entails high risk of bleeding

- Negative pregnancy test at least 14 days prior to study entry

- Informed Consent: The patient will be informed of the investigational nature of
treatment and only enter the study after agreeing to participate in the study signed
a consent form that informs the side effects and possible benefits and potential of
both modalities treatment.

Exclusion Criteria:

- Metastasis in the posterior fossa, because this patient will be operated.